single5MG
Tesamorelin
5MG Protocol
Tesamorelin 5MG
Injection Freq.
Inject once daily
Cycle Sched.
12–26 weeks; clinical trials support up to 52 weeks with monitoring
Reconstitution
2.5 mL BAC water
Reduction in visceral adipose tissue reported after 3–6 months
Improved lipid profile
potential liver-fat reduction in NAFLD research
Potential cognitive benefits in older adults (research ongoing)
Maintained benefits with continuous use up to ~52 weeks (as described)
1
Reconstitution Requirements
- 2.5 mL BAC water
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–1 | 1 mg / 1000 mcg | 50 |
| 2 | Weeks 2+ | 2 mg / 2000 mcg | 100 |
Inject once daily
12–26 weeks; clinical trials support up to 52 weeks with monitoring
Tesamorelin is presented as a GHRH-mimetic peptide that works ‘upstream’ of growth hormone. By binding to pituitary GHRH receptors, it stimulates the release of endogenous growth hormone in a pulsatile pattern and increases IGF-1 as a downstream mediator. The protocol links this cascade to increased lipolysis, improved metabolic parameters, and anabolic signaling related to protein synthesis. In clinical contexts summarized on the page—most notably HIV-associated lipodystrophy—daily dosing is described as producing measurable reductions in visceral adipose tissue and improvements in lipid profiles over several months. The page also references research into NAFLD (liver-fat reduction) and potential cognitive effects in older adults through partial restoration of GH/IGF-1 signaling that declines with age. The protocol highlights that raising IGF-1 is both part of the intended mechanism and a monitoring consideration, and it lists musculoskeletal and fluid-related side effects as the more common tolerability issues described.
Injection-site reactions (redness/itching/pain/bruising)
Joint pain and muscle aches
Peripheral edema
Carpal-tunnel–like symptoms (tingling/numbness)
IGF-1 elevation requiring monitoring
small HbA1c increases reported
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)